Extended Data Fig. 2: Impact of GSK3036656 (ganfeborole) by lesion density per participant. a, Response in cubes containing <20% voxels corresponding to air (N = 55,682). b, Response in cubes containing >20% voxels corresponding to air (cavity walls) (N = 3570). | Nature Medicine

Extended Data Fig. 2: Impact of GSK3036656 (ganfeborole) by lesion density per participant. a, Response in cubes containing <20% voxels corresponding to air (N = 55,682). b, Response in cubes containing >20% voxels corresponding to air (cavity walls) (N = 3570).

From: A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

Extended Data Fig. 2

The GSK3036656 (ganfeborole) 1 mg group (N = 6) is depicted at the top of the graphs (blue) and the 30 mg group (N = 13) at the bottom (yellow); each bar represents one participant (participants 1–19); bars below 0 indicate positive change in average lesion volume or lesion TGA. TGA, total glycolytic activity.

Back to article page